Breast Cancer

Metastatic Left Breast Carcinoma

Female, 51 years

Patient Internal ID: 201090599

ICD-10 code

C50.8 Malignant Neoplasm of Overlapping Sites of Breast

Diagnosis (Incl. Metastases/Stage) and Year

April 2021
Carcinoma of the Left Breast cT3N1M1 Stage IV G3 ER (-), PR(-), HER2 (+++), Ki67 – 50 proc. Metastases to Lungs, Mediastinum. Disease progression in December 2021, Metastasis to Left Axillary Lymph Nodes.

Previous Treatment

Chemotherapy (Docetaxel) and Biological Therapy (Pertuzumab/ Transtuzumab), Radiation Therapy, Biological Therapy (Transtuzumab).

Prognosis and Survival Expectation

The reported median survival for HER2 – Positive Metastatic Breast Cancer is ~48 months from diagnosis.

Treatment Provided

Autologous DCV (10 doses) over a period of 23 months.

Patient Survival/Condition and Year
Date of Review: 06/03/2024

The patient has survived for 35 months since the diagnosis. She continues Active Biological Therapy treatment. Regular CT scans show no signs of disease progression for a year so far and complete response of the therapy.
It can be concluded that the addition of Immunotherapy, alongside Chemotherapy and Biological Therapy, has benefited patient with disease stabilisation and complete response to therapy.